UNRESECTABLE MELANOMA

This study tests two different three-drug combinations in people with advanced melanoma that has spread or can't be removed by surgery. The drugs include immunotherapy (nivolumab) plus targeted therapies that block cancer growth signals. The goal is to see if these combinations w…

This study tests whether adding tocilizumab to two standard immunotherapy drugs (ipilimumab and nivolumab) can reduce severe side effects while still fighting cancer. About 35 adults with advanced melanoma, non-small cell lung cancer, or bladder cancer will receive the combinatio…

This study tests whether taking a break from two targeted cancer drugs (dabrafenib and trametinib) works as well as taking them continuously for people with advanced melanoma that has a specific BRAF mutation. About 280 participants with stage III or IV melanoma that cannot be su…

This early-phase study tests whether adding a drug called rigosertib to the immunotherapy pembrolizumab can help people with advanced melanoma that no longer responds to standard immunotherapy. The trial enrolled only 7 adults with melanoma that had spread or couldn't be removed.…

This study tests a personalized cell therapy called lifileucel (TIL) for people with advanced melanoma that has not responded to standard treatments. About 100 adults with stage III or IV melanoma will receive their own immune cells that have been specially grown in a lab to figh…

This study tested two different sequences of powerful drugs in 267 people with advanced melanoma that has a BRAF mutation and cannot be removed by surgery. One group started with immunotherapy (ipilimumab and nivolumab) followed by targeted therapy (dabrafenib and trametinib) if …

This study tested whether adding a drug called GM-CSF to the immunotherapy ipilimumab helps people with advanced melanoma live longer. About 245 patients with stage III or IV melanoma that could not be removed by surgery took part. The goal was to see if the combination improved …

This study tests a combination of three drugs (dabrafenib, trametinib, and navitoclax) in people with BRAF-mutant melanoma that has spread or cannot be removed by surgery, and in other solid tumors. The goal is to find the best dose and see how well the drugs shrink tumors. About…

This early-phase study tested a combination of two drugs—pembrolizumab (an immunotherapy that helps the immune system fight cancer) and ibrutinib (which blocks certain enzymes that help cancer grow)—in 20 people with advanced melanoma that could not be surgically removed. The mai…

This early-phase study tests whether combining immune-boosting drugs (nivolumab and ipilimumab) with a transplant-protecting drug (tacrolimus) can shrink or control advanced skin cancers in kidney transplant recipients. The goal is to treat the cancer while keeping the donated ki…

This study tests whether combining two immunotherapy drugs—T-VEC (a virus-based therapy injected into tumors) and pembrolizumab (an antibody given by IV)—can shrink tumors in people with advanced melanoma that no longer responds to standard immunotherapy. About 43 adults with sta…

This study looks at whether doctors can safely stop standard anti-PD-1 immunotherapy early in people with advanced melanoma that cannot be surgically removed. Using PET/CT scans and tumor biopsies as guides, the goal is to see if stopping treatment sooner still keeps the cancer u…

This trial tests a new drug, EVX-01, combined with the standard immunotherapy pembrolizumab in 17 adults with advanced melanoma that cannot be removed by surgery. The goal is to see if adding EVX-01 improves tumor shrinkage compared to historical data with pembrolizumab alone. Pa…

This early-phase study tests whether a mix of drugs and targeted radiation can help the immune system recognize and attack hard-to-treat solid tumors. About 14 adults with advanced melanoma, breast cancer, or other solid cancers that cannot be surgically removed will receive inje…

This early-phase trial tests a combination of two drugs—sonidegib and pembrolizumab—in people with advanced solid tumors that have spread. The goal is to find the safest dose of sonidegib when used with pembrolizumab and to see if the pair can shrink tumors. About 36 adults with …

This early-stage trial was designed to test the safety of a new treatment called STIL101 for people with advanced pancreatic, colorectal, kidney, cervical cancer, or melanoma that has spread or cannot be removed. The treatment uses a patient's own immune cells (T cells) taken fro…

This study is testing whether eating a high-fiber diet can change gut bacteria and improve the immune system's response to immunotherapy in people with advanced melanoma. Fifty patients starting standard immunotherapy will be randomly assigned to eat either a high-fiber diet or a…